Recent

% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

capcod3 42 posts  |  Last Activity: Feb 5, 2016 11:22 AM Member since: Nov 23, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    it's all index driven...

    by huskys4u2 Jan 13, 2016 6:26 PM
    capcod3 capcod3 Jan 14, 2016 1:23 PM Flag

    I'm not feeling rosy like you. This pps crash has made me jaded.

  • Reply to

    this is ridiculous...

    by huskys4u2 Jan 14, 2016 10:01 AM
    capcod3 capcod3 Jan 14, 2016 12:19 PM Flag

    Like I said, he expanded talk about the clinical progress on the drugs we have, but investors want action already! Enough clinical graphs. Action!

    Stoney learned nothing from DYAX pps success. My guess is he's not looking for a buyout, so pps doesn't matter.

  • Reply to

    it's all index driven...

    by huskys4u2 Jan 13, 2016 6:26 PM
    capcod3 capcod3 Jan 14, 2016 9:51 AM Flag

    To an extent that may be true for Biocryst. We fell badly due to the malaise since the dawn of 2016. January blues.
    But, Like the CEO of DeCode Genetics, our CEO is reporting good science, but he's been doing that for quite a while. The street is looking for some numbers already. It's high time. We were at 10 or 11 for a while with no real catalyst to go up or down, except for some teasers. Come January, the excuse to go negative appeared, and now we are stuck at 7. DYAX took what little they had and sold it. They are in the upper 20's. They barely got touched this year. Sorry guys, but our CEO is straightforward, honest, and intelligent; but investors are short sighted and dumb.

    February's results better be excellent, or this stock is toast!

  • Reply to

    he didn't say it...

    by huskys4u2 Jan 13, 2016 12:06 PM
    capcod3 capcod3 Jan 13, 2016 12:21 PM Flag

    yay team. breakout session coming up. pps is down!

  • Reply to

    Presentation

    by lysander_us Jan 12, 2016 12:46 PM
    capcod3 capcod3 Jan 13, 2016 10:40 AM Flag

    Weird. Manipulation perhaps?

  • Reply to

    Presentation

    by lysander_us Jan 12, 2016 12:46 PM
    capcod3 capcod3 Jan 13, 2016 10:25 AM Flag

    how many shares were traded in OT last night? Anybody?

  • Reply to

    Presentation

    by lysander_us Jan 12, 2016 12:46 PM
    capcod3 capcod3 Jan 12, 2016 4:43 PM Flag

    I hope he knows by now that "stockpile order" is the kiss of death, unless of course the order occurs!!! Fat chance until at least EOY.

  • Reply to

    Shire...

    by huskys4u2 Jan 11, 2016 11:42 AM
    capcod3 capcod3 Jan 11, 2016 12:45 PM Flag

    "Baxalta shareholders probably got a decent deal" Somebody, please explain how a deal supposedly worth 45 a share causes the pps to fall to 39.

  • Reply to

    sheeesh

    by lysander_us Jan 11, 2016 10:27 AM
    capcod3 capcod3 Jan 11, 2016 10:57 AM Flag

    Traditional biotech January dump.

  • Reply to

    Another PR

    by lysander_us Jan 8, 2016 10:28 AM
    capcod3 capcod3 Jan 8, 2016 10:30 AM Flag

    Every result is interpreted in a negative light!!! Where are you Mr. Stonehouse? Defend!!!

  • Reply to

    From A Friend...

    by huskys4u2 Jan 6, 2016 6:49 AM
    capcod3 capcod3 Jan 6, 2016 11:21 AM Flag

    So this tells me that any of the discussion by management about stockpiling has been very premature, read misleading expectations. Stockpiling changes and additions are probably a year off at least. Don't count it in the equation.

  • Reply to

    No volume, no year end love

    by lysander_us Dec 15, 2015 11:46 AM
    capcod3 capcod3 Dec 15, 2015 3:01 PM Flag

    NBI over 100 today. BCRX starts up 40 cents, then fell to even. This is the first time in weeks that BRCX has not gone up or down with the biotech indices.

  • Reply to

    information please

    by ftc12358 Dec 11, 2015 11:24 AM
    capcod3 capcod3 Dec 11, 2015 6:53 PM Flag

    Lysander - " As map says, the revenue news can come when least expected, without fanfare."
    Sorry guys, but I was just in a warm shower and a sudden chill hit me; Biocryst may not get that revenue they so long have coveted. The difference between self funding (e.g.,GILD) and govt funding projects. And it has nothing to do with GOVT. It has to do with the simultaneous funding of lots of projects, and may the best win. NIH owes Biocryst nothing. GILD went to Britain to test using their own money, after first submitting some failed HCV drugs for Ebola testing at NIH. After phase 1 success, with their own money, they can do whatever they want. That's the price Biocryst, and shareholders) pay.

    Listen up, in spite of that the pps has been pretty good.

  • Too much information. No one can ever accuse Jon of pumping! He is a straight shooter. But, maybe he shouldn't even mention anymore what the plan is if they don't get the 2 year extension on animal carcinogenicity studies.

  • Reply to

    BCRX latest comment on 4430

    by maphere Nov 20, 2015 12:52 PM
    capcod3 capcod3 Dec 3, 2015 12:23 PM Flag

    thx for the input. my problem is basically management lack of clarity. surely, more can be said than "waiting on the govt." how long do they think they can get a pass on that?

  • Reply to

    BCRX latest comment on 4430

    by maphere Nov 20, 2015 12:52 PM
    capcod3 capcod3 Dec 3, 2015 11:46 AM Flag

    I am not sure that Biocryst is on the up and up as far as BCX4430.
    Phase 1 study by Quotient in Nottingham England (see Clinicaltrials entry - updated Dec. 2) was stated to run from Dec, 2014 thru July, 2015 on 88 patients. They present as a very efficient company that runs phase 1 trials. Up till Oct, 2015 Biocryst always blames 4430 delay on the govt. Excuse me,. but clinicaltrials says Biocryst is responsible for the phase 1 study. Credibility disappears rapidly on the street.

  • Reply to

    Test Post

    by capcod3 Nov 20, 2015 10:38 AM
    capcod3 capcod3 Nov 20, 2015 11:45 AM Flag

    Agreed. I'm getting tired of the lack of fiery spirit shown by Stonehouse. Same old we're getting there attitude. Maybe BofA sees it too!

  • Reply to

    Test Post

    by capcod3 Nov 20, 2015 10:38 AM
    capcod3 capcod3 Nov 20, 2015 11:37 AM Flag

    Stonehouse saying "its the govt" is misleading. Read the article (www.acs.cen.org) and you will see that Gilead has pulled out all the stops on this and has produced a drug that works 100% in Ebola on monkeys, and may just have cured the Scottish nurse. It seems that USAMRIID prefers larger companies, especially ones with proven antivirals. It's just the way it is. Keep in mind, the ultimate goal is to get a pan-anti-RNA-virus drug, and I believe Biocryst has a shot. Just don't hold your breath waiting.

  • Reply to

    Test Post

    by capcod3 Nov 20, 2015 10:38 AM
    capcod3 capcod3 Nov 20, 2015 10:43 AM Flag

    Pardon folks, but this seems to be the only way I can get a post to stick this morning

    Treat Biocryst development of BCX4430 as a long-shot extra. It is a good thing that USAMRIID is funding the project - it means there is more than a passing interest. Don't count on it for the future of Biocryst.
    Read "Hard Lessons in Ebola Research" now appearing in the Nov. 16 issue of Chemical and Engineering News. Sina Bavari, chief scientific officer of USAMRIID, talks about Gilead's GS-5734: "If we wouldn't have found the Gilead compound, I would probably still have nightmares like I did a year ago." Scottish nurse Cafferkey was given GS-5734. She's OK now. BCX4430 is only mentioned in a "Sparse Pipeline" table.

    Again, and I quote the article - " The only new addition to the field is Gilead's GS-5734, a nucleoside inhibitor that has done a great job of helping even the sickest of infected monkeys." The text of the article mentions Tekmira, ZMapp, Fujifilm, but not Biocryst.

    Sentiment: Hold

  • capcod3 by capcod3 Nov 20, 2015 10:38 AM Flag

    Is this working

BCRX
6.14-0.36(-5.54%)Feb 5 4:00 PMEST